Renal transplantation in patients with hepatitis C virus antibody. A long national experience
J.M. Morales(Hospital Universitario 12 De Octubre), D. Seron(Vall d'Hebron Hospital Universitari), Josep M. Campistol(Universitat de Barcelona), Jorge Andrés Muñoz-Robles(Pfizer (Spain)), Federico Oppenheimer(Hospital Clínic de Barcelona), María Lorena Orellana Samaniego(Pfizer (Spain)), R Marcén(Hospital Universitario Ramón y Cajal), Axel Andrès(University of Geneva), Alejandra Gutiérrez(Hospital Universitario Miguel Servet), Beatriz Domínguez‐Gil(Universidad de Zaragoza), M.A. Gentil(Hospital Universitario Virgen del Rocío), Roberto Gallego(Hospital Universitario de Gran Canaria Doctor Negrín)
Cited by 38
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566
Donation after circulatory death today: an updated overview of the European landscape
|Transplant International|2019|317
COVID-19 pandemic and worldwide organ transplantation: a population-based study
|The Lancet Public Health|2021|312